PTC/SB/08s (08-03.)
Approved for use through 07/31/2006, OMB 0851-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

al

Lis Princet and Tragement Reduction Act of 1995, no persons are required to respond to load information unless of containing and the containing and the containing and the containing and the princet and tragement and the containing and the co

Filing Date

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)					First Named Inventor Thomas NETSCH								
					Art Unit								
					Examiner Name								
			Attorr	ey Doc	ket Numb	er	П	PHDE030426U	S				
					U.S.	PATENTS					Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Name of Patentee or Applic of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1	5151856		1992-0	9-29	Halmann,	et a	L		all			
	2	6351573	B1	2002-0	2-26	Schneider	r			all			
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click	the .	Ade	d button.		Add		
			U.S.P	ATENT	APPLI	CATION P	UBL	JC	ATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			e /ant	
	1	20020057825	A1	2002-05-16		Evron, et al.			all				
	2	20030069494	A1	2003-04-10		Jolly			all				
If you wis	h to a	l dd additional U.S. Publ	ished Ap	plication	n citatio	n informati	on p	lea	se click the Ad	d buttor	Add		
_				FORE	GN PAT	ENT DOC	UM	EN	TS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date Name of Patente Applicant of cited Document				тя			
					1	I							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number				
filing Date				
First Named Inventor	Thomas NETSCH			
Art Unit				
Examiner Name				
Attorney Docket Number		PHDF030426US		

Examinor Ctd Include name of the author (in CAPITAL LETTERS), tife of the article (when appropriate), site of the finding of the committee of the subsequence of the author (in CAPITAL LETTERS), tife of the properties of the committee of the com	Ts
9-14. ETIENNE, A., et al., "Soap Bubble" Visualization and Quantifishve Analysis of SD Coronary Magnetic Resonance.	: pp.
	, [
3 GRAVES, E.E., et al.; Registration of magnetic resonance spectroscopic maging to computed tomography for radiotherapy treatment planning; 2001; Medical Physics, 28(12):2489-2496.	
GUTTMAN, M.A., et al.: Analysis and Visualization of Cardiac Function from MR Images, 2003; http://www.mri.jhmi.eduiemcveighléocelpapers/ogs87 pdf	
If you wish to add additional non-patent literature document citation information please click the Add button Add	
EXAMINER SIGNATURE	
Examiner Signature Date Considered	

See Kind. Codes of UBPTO Patent Documents at sew UBPTO_QDV or MPEP 061.04. * Enter office that issued the document, by the Nov-liter to code (WIPO Standard ST3.). * For Lipamente patent fourament, be in chalcand on the year of the region of the Emporter many processor the small pathword of the path of the region of the Emporter many processor the small pathword of the path of the pathword of the

Application Number Fling Date Fling Date Fling Date Fling Date Fling Date Fling Number Flin

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the	appropriate selection(s):
---	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the contraction of the

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Thomas M. Lundin/	Date (YYYY-MM-DD)	2006-06-14
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2.11.450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.